Chymotrypsin (MS grade)

Chymotrypsin (EC 3.4.21.1; Chymotrypsin A) (MS grade) is an orally effective inhibitor targeting molecules such as TLR4, NF-κB, MMP-1, TNF-α, IL-1β, and IL-6. Chymotrypsin (MS grade) downregulates the TLR4/NF-κB signaling pathway, inhibits the release of inflammatory factors, reduces cell infiltration and tissue damage, and also reduces the expression of tumor cell adhesion molecules (such as CD44 and CD54). It can also be specifically detected by fluorescent probes (such as NBD-3). Chymotrypsin (MS grade) has anti-inflammatory, hepatoprotective, joint damage-reducing, liver protection against lipotoxicity, and anti-tumor metastasis functions, and can be used in the research of diseases such as rheumatoid arthritis, non-alcoholic fatty liver disease, and melanoma metastasis. Chymotrypsin (MS grade) can be used in studies of inflammation, edema, and expectoration^{[1][2][3][4][5]}. In Vitro:Chymotrypsin (MS grade) mixed with Trypsin (HY-129047) and Papain (HY-P1645) was used as a treatment group in in vitro studies (with a Chymotrypsin (MS grade) content of 0.2 mg/0.1 mL), causing a decrease in CD44 expression in SMMU-2, SK-MEL 28, B16F10 melanoma cells, MOLT 4/8 leukemia cells, and breast cancer cells^[3].
Chymotrypsin (MS grade) selectively reduces the density of CD4, CD44, and CD80 molecules in peripheral lymphocytes^[3].
Chymotrypsin (MS grade) can be detected by the probe NBD-3 (2 mM), with a detection concentration of 0-6 g/mL and a reaction time of 20 minutes, producing red fluorescence at 634 nm under an excitation wavelength of 550 nm, with a detection limit of 15. ng/mL. Furthermore, its activity can be inhibited by the inhibitor phenylmethylsulfonyl fluoride (PMSF)^[4]; In Vivo:Chymotrypsin (MS grade) (0.53 mg/kg, 1.06 mg/kg; injected into the plantar surface of the left hind paw) reduces joint damage, inhibited paw swelling and arthritis scores, and reduces pathological changes such as synovial hyperplasia and inflammatory cell infiltration in a Sprague-Dawley rat adjuvant-induced arthritis (AIA) model. Chymotrypsin (MS grade) also downregulates the protein and mRNA expression of MMP-1, TNF-α, IL-1β, IL-6 in serum and TLR4, NF-κB in synovial tissue^[1].
Chymotrypsin (MS grade) (in combination with trypsin, 3 EAU/kg; oral gavage; once daily; 5 weeks) protectes the liver from damage in an olanzapine-induced non-alcoholic steatohepatitis (NASH) model in young adult male albino rats, significantly reducing olanzapine-induced elevated ALT, AST, ALP, total cholesterol, and LDL-C, reducing steatosis scores and hepatocyte necrosis, increasing Ki67 expression, and not affecting the memory function of the rats^[2].
Chymotrypsin (MS grade) (mixed with trypsin and papain, 0.2 mg/0.1 mL mixture; rectal administration; twice daily; 100 days) inhibits primary tumor growth, reduces tumor recurrence and metastasis (including lung and distant metastasis), prolongs mouse survival time, and reduced the expression of CD44 and CD54 molecules in tumor cells in a B16 melanoma metastasis model in female inbred C57Bl6 mice^[3].
The NBD-3 probe detects endogenous chymotrypsin in mouse liver^[4].